Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gilteritinib Rollover Study
NCT02561455Phase 2Completed
- Sponsor
- Astellas Pharma
- Start
- May 2016
- Primary completion
- Jul 2020
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of gilteritinib in acute myeloid leukemia (AML), solid tumor (advanced stage), sponsored by Astellas Pharma. Started May 2016; status: completed.
02
Drugs
gilteritinib
03
Conditions
acute myeloid leukemia (AML)solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT02561455.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02561455.